Summit Appoints Robert W. Duggan as Chief Executive Officer

Summit Therapeutics plc 
(‘Summit’ or the ‘Company’)

Summit Appoints Robert W. Duggan as Chief Executive Officer

Oxford, UK, and Cambridge, MA, US, 14 April 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr Robert (Bob) Duggan has been appointed Chief Executive Officer (‘CEO’) of Summit Therapeutics, effective immediately. Mr Duggan will retain his role as Chairman of the Board. Mr Duggan will serve as CEO without compensation as he is Summit’s leading shareholder.

Mr Glyn Edwards has tendered his resignation, which will be effective immediately.

Mr Duggan, on behalf of the Summit, thanks Glyn Edwards for his eight years of service. Mr. Edwards will continue to serve as an elected Board Member to the Company.

Mr Duggan states the following, “To build a viable Summit Therapeutics company will require, amongst many other factors, bringing on additional seasoned executives as well as raising additional financial capital over time. The anti-infective disease medicinal drug business has plus points as well as challenges. Initial disease cures are plus points. Lack of sustained cures caused by disease recurrence and when combined with ever growing multi spectrum drug resistance, in my opinion, form the Achille’s heel of today’s FDA approved anti-infective drugs.”

Mr Duggan further stated that, “Summit Therapeutics knows that something positive can be done about the outpoints. Summit Therapeutics is engaged in very significant work. Infectious disease patients are in need of durable cures. Caregivers are in search of and in need of durable cures. Payers are in need of cost-effective medicinal drugs that substantially reduce the heavy financial burden of early disease recurrence post anti-infective drug treatment.”

Mr Duggan concluded by saying that, “Summit Therapeutics has the potential and intends to play a meaningful role in this needed and wanted new era of increasingly patient friendly anti-infective drug therapy.”

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, Enterobacteriaceae and N. gonorrhoeae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.